StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Gyre Therapeutics's R&D Expenses for the twelve months ending Mar 31, 2026 was $27.70M, up 114.1% year over year. For fiscal 2025 it was $13.70M, up 13.9% from the year before. Over ten years it grew 8.7% a year on average. The highest annual figure on record is $95.22M in fiscal 2011.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.70M+13.9%
FY2024Dec 31, 2024$12.02M-12.7%
FY2023Dec 31, 2023$13.78M-17.4%
FY2022Dec 31, 2022$16.69M-75.8%
FY2021Dec 31, 2021$68.89M+30.0%
FY2020Dec 31, 2020$52.98M+20.8%
FY2019Dec 31, 2019$43.86M+104.2%
FY2018Dec 31, 2018$21.47M+67.2%
FY2017Dec 31, 2017$12.85M+11.2%
FY2016Dec 31, 2016$11.56M+93.9%
FY2015Dec 31, 2015$5.96M+13.1%
FY2014Dec 31, 2014$5.27M-19.7%
FY2013Dec 31, 2013$6.56M-86.6%
FY2012Dec 31, 2012$49.09M-48.4%
FY2011Dec 31, 2011$95.22M+47.5%
FY2010Dec 31, 2010$64.55M+60.6%
FY2009Dec 31, 2009$40.18M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$6.74M+117.7%
Q4 FY2025Dec 31, 2025$4.82M+29.7%
Q3 FY2025Sep 30, 2025$7.80M+181.0%
Q2 FY2025Jun 30, 2025$8.35M+148.9%
Q1 FY2025Mar 31, 2025$3.10M+41.8%
Q4 FY2024Dec 31, 2024$3.71M-18.7%
Q3 FY2024Sep 30, 2024$2.78M-7.8%
Q2 FY2024Jun 30, 2024$3.36M-6.0%
Q1 FY2024Mar 31, 2024$2.18M-17.2%
Q4 FY2023Dec 31, 2023$4.57M+6.0%
Q3 FY2023Sep 30, 2023$3.01M+274.7%
Q2 FY2023Jun 30, 2023$3.57M+90.7%
Q1 FY2023Mar 31, 2023$2.64M-72.8%
Q4 FY2022Dec 31, 2022$4.31M-73.3%
Q3 FY2022Sep 30, 2022$803.00K-96.1%
Q2 FY2022Jun 30, 2022$1.87M-87.8%
Q1 FY2022Mar 31, 2022$9.70M-43.0%
Q4 FY2021Dec 31, 2021$16.14M+10.8%
Q3 FY2021Sep 30, 2021$20.35M+66.2%
Q2 FY2021Jun 30, 2021$15.39M+19.2%
Q1 FY2021Mar 31, 2021$17.01M+28.3%
Q4 FY2020Dec 31, 2020$14.56M+34.9%
Q3 FY2020Sep 30, 2020$12.25M+23.4%
Q2 FY2020Jun 30, 2020$12.91M+16.2%
Q1 FY2020Mar 31, 2020$13.26M+10.3%
Q4 FY2019Dec 31, 2019$10.79M+31.0%
Q3 FY2019Sep 30, 2019$9.93M+78.1%
Q2 FY2019Jun 30, 2019$11.11M+185.7%
Q1 FY2019Mar 31, 2019$12.03M+218.9%
Q4 FY2018Dec 31, 2018$8.24M+131.4%
Q3 FY2018Sep 30, 2018$5.58M+46.5%
Q2 FY2018Jun 30, 2018$3.89M+14.3%
Q1 FY2018Mar 31, 2018$3.77M+83.0%
Q4 FY2017Dec 31, 2017$3.56M+14.4%
Q3 FY2017Sep 30, 2017$3.81M–
Q2 FY2017Jun 30, 2017$3.40M–
Q1 FY2017Mar 31, 2017$2.06M–
Q4 FY2016Dec 31, 2016$3.11M–

More Gyre Therapeutics figures

See a number that looks wrong?